Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide added to second-line hormonal therapy in non-metastatic castration-resistant prostate cancer with elevated chromogranin A
2010-019862-10Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Dec 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lanreotide in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Progression-free survival. Started Dec 2010; status: terminated.
02
Drugs
lanreotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-019862-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019862-10.